Phoenix Molecular Designs is pleased to announce that we are now a member of the TuneLab platform from Eli Lilly and Company. TuneLab provides access to artificial intelligence (AI) and machine learning (ML)–enabled small-molecule ADMET prediction and antibody property prediction models built on decades of pharmaceutical research data.

Participation in TuneLab represents an important opportunity to further strengthen how Phoenix applies data-driven insights to advance our precision oncology pipeline and support early-stage drug discovery efforts.

We thank Vanessa Braunstein and the Lilly team for their collaboration and the opportunity to connect at Biocom’s conference.

Learn more about TuneLab:
https://tunelab.lilly.com/